Wire · opportunities
PD-L1 Biomarker Testing Market to Grow at 8.3% CAGR Through 2034
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 29 August 2026 · Fusion42 review
The PD-L1 biomarker testing market is projected to grow at an 8.3% CAGR to reach USD 1.6 billion by 2034, driven by increasing cancer incidence and adoption of precision oncology tests with advances in digital pathology and AI. North America leads this growth, supported by regulatory approvals and widespread use of companion diagnostics in immunotherapy.
This Wire brief sits within Fusion42's coverage of Diagnostics.
◆ ◆ The Wire takeaway
Your cancer diagnostics startup must adopt AI-powered PD-L1 testing soon to match improving test accuracy and workflow efficiency. Regulatory momentum in North America opens opportunities to integrate companion diagnostics into immunotherapy pathways for faster market access.
◆ Coverage
1 source · 29 Aug 2026
◆ Related on Wire
◆ Topics